Glycolysis-Activating Agents Enhance Treg Migration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
The bioenergetics of regulatory T cell (Treg) trafficking remains undefined, particularly in terms of metabolic demands during migration, which is crucial for their immune-modulatory function, and existing technologies lack effective methods to enhance Treg migration for immune-mediated disease treatment.
Innovation Solution
Activation of glycolysis in Tregs through glycolysis-activating agents, such as glucokinase activators, to promote metabolic reprogramming and enhance migration to inflamed tissues, utilizing compounds like AZD1656 to stimulate glycolytic pathways and regulate Treg motility.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Speed
If Treg cells rely on oxidative metabolism, then they maintain immunomodulatory function, but their migratory ability to inflamed tissue is limited
Solution Approach 1:
The patent applies parameter changes by shifting the metabolic state of Treg cells from oxidative metabolism to glycolytic metabolism. This is achieved through activating glucokinase (a rate-limiting enzyme in glycolysis) using specific activator compounds, which changes the energy metabolism parameters of Treg cells to support enhanced migratory function while maintaining their immunomodulatory role.
2Reliability
If Treg migration is enhanced for immune regulation, then disease treatment efficacy improves, but understanding of metabolic demands remains undefined
Solution Approach 1:
The patent uses glucokinase activator compounds as intermediary substances to bridge the gap between understanding Treg metabolism and enhancing Treg migration. These small molecule activators serve as mediators that specifically target and activate glucokinase in Treg cells, thereby enabling enhanced migration to inflamed tissues while providing a controllable and measurable therapeutic approach.
3Speed
If glycolysis is activated in Tregs, then migratory activity increases, but metabolic reprogramming mechanisms remain to be fully elucidated
Solution Approach 1:
The patent extracts and targets the specific rate-limiting step in glycolysis (glucokinase activity) as the key control point for metabolic reprogramming. By focusing on this single enzymatic step rather than attempting to control the entire complex glycolytic pathway, the invention simplifies the approach to enhancing Treg migration while achieving effective metabolic reprogramming through targeted glucokinase activation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The activation of glycolysis in Tregs increases their migratory activity and immune-modulatory function, effectively treating or preventing immune-mediated diseases by enhancing Treg trafficking to target tissues, thereby improving disease outcomes.
Implementation Method 1
The process of glycolysis is controlled in part by the enzyme glucokinase (GCK or GLK). The rate of glucose uptake is limited by the rate of phosphorylation of glucose to glucose-6-phosphate (G6P), a process which is catalysed by GCK.
Implementation Method 2
The rate of glucose uptake is limited by the rate of phosphorylation of glucose to glucose-6-phosphate (G6P), a process which is catalysed by GCK.
Data Source
AI summary
The present invention relates to glycolysis-activating agents. The present invention also relates to the treatment or prevention of diseases or medical conditions, in particular immune-related diseases or medical conditions. In particular, the present invention also relates to agents for use in the treatment or prevention of a disease or medical condition, which treatment or prevention is mediated via the trafficking of endogenous regulatory T cells (Tregs).